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Abstract
Introduction: The aim of this study was to derive a novel prognostic score for mortality in paediatric
meningococcal sepsis (MS) based on readily available laboratory markers.
Methods: A multicentre retrospective cohort study for the consortium set and a single centre retrospective study
for replication set. The consortium set were 1,073 children (age 1 week to 17.9 years) referred over a 15-year period
(1996 to 2011), who had an admission diagnosis of MS, referred to paediatric intensive care units (PICUs) in six
different European centres. The consortium set was split into a development set and validation set to derive the
score. The replication set were 134 children with MS (age 2 weeks to 16 years) referred over a 4-year period (2007
to 2011) to PICUs via the Children’s Acute Transport Service (CATS), London.
Results: A total of 85/1,073 (7.9%) children in the consortium set died. A total of 16/134 (11.9%) children in the
replication set died. Children dying in the consortium set had significantly lower base excess, C-reactive protein
(CRP), platelet and white cell count, more deranged coagulation and higher lactate than survivors. Paediatric risk of
mortality (PRISM) score, Glasgow meningococcal septicaemia prognosis score (GMSPS) and Rotterdam score were
also higher. Using the consortium set, a new scoring system using base excess and platelet count at presentation,
termed the BEP score, was mathematically developed and validated. BEP predicted mortality with high sensitivity
and specificity scores (area under the curve (AUC) in the validation set = 0.86 and in the replication set = 0.96). In
the validation set, BEP score performance (AUC = 0.86, confidence interval (CI): 0.80 to 0.91) was better than
GMSPS (AUC = 0.77, CI: 0.68, 0.85), similar to Rotterdam (AUC = 0.87, CI: 0.81 to 0.93) and not as good as PRISM
(AUC = 0.93, CI: 0.85 to 0.97).
Conclusions: The BEP score, relying on only two variables that are quickly and objectively measurable and readily
available at presentation, is highly sensitive and specific in predicting death from MS in childhood.
Introduction
Despite vaccination against Neisseria meningitidis ser-
ogroup C, meningococcal sepsis (MS) with non-vaccine
serogroups, particularly serogroup B, remains a major
public health challenge. Meningococcal disease can evolve
extremely rapidly, with non-specific symptoms evolving
into severe sepsis with multiple organ failure within hours.
Much attention has rightly been devoted to the develop-
ment of an effective vaccine and to the education of the
lay public and medical staff to help identify and act on
symptoms of early disease. However in the UK, despite
these measures, there are still around 1,000 cases of
meningococcal sepsis every year, with about 200 children
requiring intensive care. The case fatality rate is 5 to 10%
and of those who survive, 10 to 20% develop permanent
sequelae, including skin scars, limb amputation, hearing
loss, seizures and brain damage [1,2].* Correspondence: d.inwald@imperial.ac.uk2Department of Paediatrics, Imperial College, Norfolk Place, London W2 1PG,
UK
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A reliable prognostic scoring system would have two
main purposes - first, to identify patients at high risk of
deterioration, and second, for risk stratification in future
trials of novel therapies in sepsis [3]. Previous clinical trials
of specific novel therapies in meningococcal sepsis, target-
ing pathways of inflammation and coagulation such as
recombinant bactericidal/permeability-increasing protein
(rBPI) [4] and human activated protein C (rhAPC) [5],
have failed for reasons which are not clear, but which may
include case mix. Currently, therefore, therapy consists of
antibiotics and supportive treatments only. Future trials of
novel therapies in MS and indeed in other forms of bacter-
ial sepsis are likely to succeed only if patients at high risk
of severe disease are identified and enrolled, rather than
patients reliably predicted to survive or die.
More than 20 previous studies have looked at factors
which might be predictive of mortality in MS. These have
included scoring systems which combine clinical data with
laboratory data including the Glasgow meningococcal sep-
ticaemia prognostic score (GMSPS) [6] and the paediatric
risk of mortality (PRISM) score [7], amongst numerous
others (Table 1). The PRISM score, which is a general pae-
diatric intensive care unit (PICU) severity of illness score,
has been validated in MS [8]. Scoring systems solely based
on laboratory markers include the product of the platelet
and neutrophil count (the PN score) [9] and the Rotter-
dam score, based on potassium, base excess, platelet count
and C-reactive protein (CRP) [10]. More recently, scores
based on biomarkers have been proposed [11]. While bio-
marker scores can be highly accurate and are scientifically
attractive, they are not useful at the point of presentation
as the assays on which they depend take time to run. An
ideal score would include a small number of variables that
are quickly and objectively measurable, readily available at
presentation and cost-effective.
Unfortunately, previous studies developing and testing
such prognostic scoring systems have in the past not
investigated large numbers of patients, the largest previous
study looking at only 278 children [12]. Furthermore,
PRISM, GMSPS and many of the other clinical or com-
bined scoring systems depend to an extent on subjective
assessments which may not be reliable. For example,
GMSPS includes the variable ‘parental opinion that child’s
condition has become worse over the past hour’. PRISM
requires entry of multiple data points into a complex algo-
rithm and thus is less attractive in emergency settings.
As part of a large European study of genetic factors
contributing to disease severity and susceptibility in
meningococcal disease, clinical and scoring data became
available in a unique and substantial cohort of patients
referred to PICUs in the United Kingdom, Austria, Ger-
many and Holland [13].
The aim of this current study was to identify factors
predictive of death in this population, including current
Table 1 Data points used in the different scoring systems discussed in this paper.
Data point PRISM GMSPS Rotterdam BEP
Base deficit √ (> 8 mmol/L) √ √
HCO3 √
Platelets √ √
Potassium √ √
CRP √
Systolic BP √ √ (< 75 mmHg)
Diastolic BP √
GCS √ √ (< 8)
Heart rate √
Resp rate √
PaO2/FiO2 √
PaCO2 √
PT/PTT √
Bilirubin √
Calcium √
Glucose √
Pupil reaction √
Skin/rectal temp > 3 degrees √
Lack of meningism √
Parents opinion child is worse √
Ecchymoses √
Paediatric risk of mortality (PRISM), Glasgow meningococcal septicaemia prognosis score (GMSPS), Rotterdam score and base rate and platelet count (BEP) score.
CRP, C-reactive protein; BP, blood pressure; GCS, Glasgow coma score; PT, prothrombin time: PTT, partial thromboplastin time.
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scoring systems, when data was available. A new score
was developed and validated using an independent
cohort of patients referred to PICU via the North
Thames regional retrieval service, the Children’s Acute
Transport Service, London, UK (CATS).
Materials and methods
Patients
Data was collected prospectively (and analysed retrospec-
tively) from children referred to PICUs at participating
centres over the 15-year study period, 1996 to 2011.
Participating centres included St Mary’s Hospital
(London, UK), Alder Hey Children’s Hospital (Liverpool,
UK), Medical University of Graz (Graz, Austria),
Erasmus-MC Sophia Children’s Hospital (Rotterdam,
Holland) Emma Children’s Hospital (Amsterdam,
Holland) (the ‘consortium’) and the Children’s Acute
Transport Service (CATS, London, UK). Clinical and
other data in consortium patients were collected during
ongoing studies at each hospital, approved by the institu-
tional ethics committee for each participating centre.
Informed consent was obtained for these patients accord-
ing to local regulations. Retrospective data collection at
CATS was approved by the Great Ormond Street Hos-
pital for Children Clinical Audit Committee. Parental
consent was deemed to be unnecessary for patients retro-
spectively included in this anonymised observational
study. Each centre collected and recorded data into their
own databases before entering anonymised data onto a
centralised web-based data collection system (Dataphiles,
Otley, UK).
Definitions
Any child referred to PICU with a clinical diagnosis of
MS was eligible for inclusion. The clinical diagnosis of
MS required the presence of fever and haemorrhagic
rash together with clinical features of severe sepsis or
septic shock, according to the criteria described by
Goldstein et al. [14]. Children with isolated meningitis
without sepsis physiology were excluded from the
analysis.
Data
Anonymised data exports from the participating centres’
databases were sent and uploaded into a central database
held at Imperial College London for further analysis.
Data included in the anonymised export were demo-
graphic data (age, sex, admission date, ethnic origin),
diagnostic data (sepsis or meningitis as main presenting
feature, serogroup of organism if available), clinical
scores (PRISM, GMSPS and Rotterdam score), laboratory
data (platelet count, white cell count, lactate, base excess
coagulation profile, fibrinogen, potassium, CRP) and out-
come data (survival). Unfortunately, outcomes other than
death, including important morbidities such as skin loss
requiring grafting or limb amputation, were not reliably
recorded and hence could not be investigated in this
study. Laboratory data, from the first recorded sample,
were measured in each centre according to standard
techniques.
Statistical analysis
Differences within the study groups were analysed with
the t-test for unequal variance. Robust estimation of the
area under the curve (AUC) of the receiver operating
characteristic (ROC) was computed and its 95% confi-
dence interval (CI) was estimated using a bootstrap
method implemented in the R statistical package [15].
The statistical significance of the AUC was assessed
using the Mann-Whitney test. The best cutoff point
according to the Youden’s statistic was defined as pre-
viously described [16]. Calibration of the model was
assessed using Cox’s calibration regression in the R statis-
tical package.
Development and validation datasets
All records in the consortium set containing complete
information on all laboratory variables plus gender were
used as the development set (n = 309). The remainder
of the records was used as the validation set (n = 623)
(see Figure 1).
Variable selection and survival prognosis score
Bayesian model averaging (BMA) for generalised linear
models [17] was applied to the development set to identify
variables significantly (a = 0.05) associated with survival
outcome [15]. All available laboratory variables were
included in this analysis (Figure S1 in Additional file 1).
Logistic regression analysis was conducted to determine
whether other study variables, including study centre, year
of admission, age, weight and sex were associated with
death. The new prognosis score was based on a logistic
regression model developed using the selected laboratory
variables and fit to the development set.
Survival prognosis score assessment on the validation
dataset
The new prognosis score was assessed in the validation
dataset and ROC curves as well as the AUC were com-
pared with other benchmark prognosis scores from the
literature using a bootstrap test for two paired ROC
curves [18]. Monte Carlo cross validation was used to
assess the performance of the logistic regression model
on unseen data [19]. In the Monte Carlo analysis, data of
the validation set was randomly split into equal train and
test sets and the regression model was fit to the train set
and evaluated on the test set (Figure 1). On each test set
randomly generated, a performance statistic based on
AUC test statistics described by DeLong et al. [20,21]
was computed for the paired comparison between the
new score and the benchmark score. This procedure was
Couto-Alves et al. Critical Care 2013, 17:R68
http://ccforum.com/content/17/2/R68
Page 3 of 11
repeated 105 times to obtain a distribution of the perfor-
mance statistic in the validation set.
Replication set
A ROC curve using the model was produced from a
recent replication dataset of 134 patients referred to
CATS, comprising 16 non-survivors and 116 survivors.
Results
A total of 1,073 children (age 1 week to 17.9 years) with
meningococcal sepsis were in the consortium set. Of
these, 85 (8%) died; 581 (54%) were male. Demographics,
clinical scores, laboratory data, interventions and out-
come data are shown in Table 2. Eight children had
Group A disease, 419 had Group B, 215 had Group C, 8
had W135, 4 were YW135 and 13 were logged as having
positive cultures but no serogroup was available. The his-
tograms of the laboratory data are shown in Figure S1 in
Additional file 1. A total of 134 children (age 2 weeks to
16 years) were in the CATS replication set, of whom 16
(12% died). Details of the replication set are shown in
Table 3.
Development of a new score
A model built using BMA for logistic regression with
binomial distribution prior probability (P = 0.5) of inclu-
sion of a variable was fitted to the records of the develop-
ment dataset with complete information for all variables
(n = 309). The posterior probability of the model coeffi-
cients was analysed to identify variables to be included in
the new prognosis score. Supplementary Figure S2 shows
the posterior probability distribution of each variable coef-
ficient (Figure S2 in Additional file 2). The variables that
were most statistically important (a = 0.05), base excess
(BE) and platelets, were used to build a model using logis-
tic regression, termed the BEP score. The fitted model was
statistically significant (likelihood ratio test P < 0.001,
Figure 1 Methodology. Data from two sources were collected: data contributed by consortium members (development and validation set) and
by the Children’s Acute Transport Service (replication set). Development set is subdivided into two sets. The complete records set includes those
with complete information for all variables collected. Validation records are those records that include complete information for base excess (BE)
and platelets but are not all variables.
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Hosmer-Lemeshow chi-square test = 20.2, P = 0.009) with
considerable goodness of fit (Nagelkerke pseudo-R2 = 0.3
and Brier score = 0.046). Calibration of the BEP score on
the entire consortium dataset shows a relatively small
underestimation of the probability of death for BEP > 0.3
(the mean absolute error is 0.025 and the 0.9 quantile of
the absolute error is only 0.066, (Figure S3 in Additional
file 3). We tested for confounding or study design effects
and did not find any association with study centre, year of
admission, age, weight or sex (P > 0.6 for all variables).
BEP score regression coefficient analysis
We estimated the coefficients of the logistic regression
model in the entire development dataset. Overall, the
statistical significance of the variables is high and stan-
dard error of the coefficients is low, indicating that the
choice of variables used in the model is appropriate and
that the values of the coefficients are robust (data not
shown). Using this analysis, the BEP score is mathemati-
cally defined as:
P (death) = 1
/(
1 + e(0.18909 × BE)+ (0.01015 × Platelets) +3.07861
)
BEP score cutoff
The performance of the BEP score for a range of cutoffs
((0.1 to 0.5)) was estimated on the development, valida-
tion and replication datasets (Table 4). For a cutoff as
low as BEP > 0.3 a good discriminating performance
can be achieved on all datasets positive predictive value
((PPV) > 0.5, negative predictive value (NPV) > 0.94). A
contour plot of the BEP score probability of death as a
function of BE and platelet count is shown for quick
reference (Figure 2). The cutoff Θ that maximizes the
Youden’s statistic was estimated on the development
dataset using the following equation: Θ = arg max (Sen-
sitivity (Θ) + Specificity (Θ) -1). The cutoff was then
applied to the validation and replication dataset and
results are presented in Table S1 (Table S1 in Addi-
tional file 4). Overall, a good performance was consis-
tently obtained in the validation and development
datasets. Sensitivity confidence intervals obtained in the
validation dataset includes the point estimates of the
development dataset. Specificity confidence intervals
obtained in development and validation datasets overlap
and PPV was higher in the validation and replication
dataset.
Table 2 Demographic and other features of the study population, according to survival (mean with 95% confidence
intervals shown, t-test with unequal variance).
Whole population Died Survived P value
Sex (male, %) 581/1073 (54%) 52/85 (61%) 529/988 (54%) 0.18 (chi square)
Decimal age (years) 5.12 ± 0.30 5.75 ± 1.3 5.06 ± 0.3 0.36
PRISM 12.7 ± 1.2 61.9 ± 6.7 11.0 ± 1.3 < 0.001
GMSPS 7.9 ± 0.2 11.4 ± 7.6 ± 0.3 < 0.001
Rotterdam 13.5 ± 1.6 59.1 ± 8.3 10.2 ± 1.3 < 0.001
WCC (109/L) 14.5 ± 1.3 6.7 ± 1.5 15.1 ± 1.4 < 0.001
Platelets (1012/L) 197 ± 7 100 ± 19 206 ± 6.7 < 0.001
APTT (s) 53 ± 2 104 ± 15 50 ± 2 < 0.001
INR 1.7 ± 0.05 2.7 ± 0.4 1.6 ± 0 < 0.001
Fibrinogen (g/L) 3.7 ± 0.1 1.6 ± 0.4 3.9 ± 0.1 < 0.001
CRP (mg/dL) 107.3 ± 4.8 68.7 ± 12.1 110.1 ± 5 < 0.001
K (mmol/L) 3.7 ± 0 3.9 ± 0.3 3.6 ± 0 0.56
Base excess (mmol/L) -6.9 ± 0.3 -12.1 ± 1.2 -6.5 ± 0.3 < 0.001
Lactate (mmol/L) 3.7 ± 0.2 7.2 ± 0.9 3.7 ± 0.2 < 0.001
Ventilation 627/1073 (58%) 80/85 (94%) 547/988 (55%) < 0.0001 (chi square)
Inotropes 675/1073 (63%) 78/85 (96%) 597/988 (60%) < 0.0001 (chi square)
PRISM, paediatric risk of mortality; GMSPS, Glasgow meningococcal septicaemia prognosis score; WCC, white cell count; APTT, activated partial thromboplastin
time; INR, international normalised ratio; CRP, C-reactive protein.
Table 3 Details of replication set from the Children’s Acute Transport Service, according to survival (mean with 95%
confidence interval shown, t-test with unequal variance).
Whole population Died Survived P value
Sex (male, %) 79/134 (59%) 7/14 (50%) 72/120 (60%) 0.47 (chi square)
Decimal age (years) 3.25 ± 0.59 2.48 ± 0.52 3.35 ± 0.6 0.31
Platelets (1012/L) 205 ± 20 46 ± 8 227 ± 19 < 0.001
Base excess (mmol/L) -7.4 ± 0.8 -15.4 ± 1.0 -6.3 ± 0.6 < 0.001
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Table 4 Base excess and platelet count (BEP) performance for different cutoffs on the development, validation and
replication datasets.
Dataset BEP N Sensitivity Specificity Positive predictive value Negative predictive value
> 0.1 50 0.65 0.88 0.29 0.97
> 0.2 21 0.44 0.96 0.45 0.96
Development > 0.3 8 0.26 0.99 0.6 0.94
> 0.4 4 0.15 1 0.75 0.94
> 0.5 2 0.05 1 0.55 0.93
> 0.1 110 0.67 0.87 0.29 0.97
> 0.2 64 0.57 0.94 0.43 0.96
Validation > 0.3 30 0.35 0.98 0.55 0.95
> 0.4 21 0.29 0.99 0.68 0.95
> 0.5 11 0.17 1 0.78 0.94
> 0.1 25 0.85 0.9 0.4 0.99
> 0.2 16 0.8 0.97 0.7 0.98
Replication > 0.3 11 0.56 0.98 0.72 0.97
> 0.4 9 0.48 0.99 0.79 0.96
> 0.5 6 0.36 1 1 0.95
N denotes the number of individuals with BEP score greater than the selected cutoff (for example on the validation dataset there are 110 subjects with a BEP > 0.1).
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Figure 2 Contour plot showing the probability of death for different ranges of base excess and platelet count (BEP) score. Notice for
BEP > 0.15, the probability of death increases progressively for the same change in the variables.
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Performance analysis of the scores on the validation data
The validation dataset was used to compare the perfor-
mance of the different scores. These data consists of
623 individuals, 51 non-survivors and 572 survivors.
ROC curves were generated for each score (Figure 3).
BEP score performance (AUC = 0.86, CI: 0.80 to 0.91)
was better than GMSPS (AUC = 0.77, CI: 0.68, 0.85),
followed by Rotterdam (AUC = 0.87, CI: 0.81 to 0.93)
and PRISM (AUC = 0.93, CI: 0.85 to 0.97). The boot-
strap test for paired ROC curves demonstrated that BEP
score was statistically significantly different from
GMSPS (P = 0.03) but not significantly different from
Rotterdam and PRISM (P = 0.68 and P = 0.22 respec-
tively). The Monte Carlo cross validation analysis of the
entire validation set (n = 623) demonstrated similar
results (Figure S4 in Additional file 5), with BEP score
AUC significantly different to PRISM (P = 0.04), almost
significantly different to GMSPS (P = 0.056) but not dif-
ferent to Rotterdam (P = 0.541). Taken together, these
results suggest that the BEP score is more accurate than
GMSPS, equivalent to Rotterdam and not quite as accu-
rate as PRISM.
Replication of the BEP score performance on out-of-
sample data
A replication dataset of 134 additional records from
CATS were collected comprising 16 non-survivors and
116 survivors. The performance of the BEP score was
evaluated using AUC and the ROC curve (Figure 4).
The AUC on the replication dataset (AUC = 0.96, CI:
0.90 to 0.99).
Discussion
Numerous studies have looked at factors predictive of
poor outcome in meningococcal disease, since the semi-
nal study of Stiehm and Damrosch in 1966, which iden-
tified petechiae, hypotension, absence of meningitis,
peripheral leukopenia and low erythrocyte sedimentation
rate (ESR) as markers of a poor prognosis [22]. Since
then, in the developed world, the case fatality rate from
meningococcal disease has fallen from over 50% to
under 10%, largely due to improvements in diagnosis
and supportive therapy [23,24]. However, trials of speci-
fic adjunctive therapies have not demonstrated any ben-
efit. One reason for this may have been a failure to
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Figure 3 Receiver operating characteristic (ROC) curve of each score on the validation set (n = 623).
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select a study population in whom neither death nor
survival was inevitable. Therefore, any scoring system
which helps to identify such populations may be of ben-
efit in future clinical trials. Identification of populations
of patients at high risk of death may also be useful for
genetic studies looking at associations between genotype
and disease severity.
Early studies developing prognostic scores in menin-
gococcal sepsis tended to focus on clinical factors indi-
cative of shock, which are amenable to supportive
treatments, such as fluid loading, inotropic support and
mechanical ventilation. One relatively recent study look-
ing at laboratory markers focused on platelet and neu-
trophil count [8], and suggested that in an age of
improved recognition and management of disease, mar-
kers of endothelial dysfunction were more useful than
clinical markers of poor perfusion, the former represent-
ing pathophysiology not amenable to any specific treat-
ment. However, GMSPS and PRISM, and scoring
systems which combine clinical and laboratory markers
continue to have clinical utility [25,26]. Clearly, an accu-
rate scoring system using a small number of variables
which are rapidly available soon after the patient comes
through the doors of the Emergency Department will
have more utility than a score dependent on multiple
variables, some of which may be difficult or slow to
measure, require repeated measurement or which rely
on subjective assessment.
In this study, the largest to date in meningococcal sep-
sis, a new and extremely simple scoring system is pro-
posed. This new score, termed the BEP score, is solely
based on base excess and platelet count, both very easy
to measure variables which represent tissue hypoperfu-
sion and endothelial damage respectively. With an AUC
of 0.86 in the validation set and 0.96 in the replication
set, BEP performed significantly better than GMSPS,
similarly to Rotterdam score, and not as well as PRISM.
BEP also performed similarly to PN product in its origi-
nal description looking at patients admitted prior to
1999, in which PN product was demonstrated to have
an AUC of 0.97 in the development set and 0.89 in the
validation set [9]. Unfortunately, we were unable to look
at the PN score in our patients as absolute neutrophil
count was not consistently available in our dataset.
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Figure 4 Receiver operating characteristic (ROC) curve of the base excess and platelet count (BEP) score on the replication dataset
(n = 134).
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In our population PRISM had an AUC of 0.93, having
previously been described as anywhere between 0.80
[26] to 0.95 [8]. This indicates that despite being devel-
oped 25 years ago, PRISM remains a reliable score. Its
main disadvantages are that it requires collection and
entry of multiple data points into a complex algorithm
and that it has not been validated in a pre-PICU setting.
GMSPS, which has some constituent variables which are
notoriously difficult to measure objectively, has been
reported to have an AUC from 0.96 [12] to 0.81 [9] in
previous studies, with a tendency to decrease from the
1980s to the present day. In our population GMSPS had
an AUC of 0.77. This continued fall in the performance
of GMSPS may be because of ongoing improvements in
disease recognition and in initiation of supportive treat-
ments, or other as yet unidentified factors. The Rotter-
dam score had intermediate reliability in our validation
set, with an AUC of 0.87. Unfortunately, there is no his-
torical AUC to compare with Rotterdam score, AUC
being unreported in the initial study describing the
score [10].
Limitations
The most important limitation of this study is the fact
that ‘first recorded sample’ is not clearly defined, the
data consisting of multiple datasets from several Eur-
opean countries. While in some datasets the first
recorded sample is that taken on presentation in the
Emergency Department, in others the first sample was
from the ICU admission. However, given the natural
history of meningococcal disease, these time points are
unlikely to have been more than a few hours apart.
Additionally, the type of blood gas sample (whether
arterial, capillary or venous), the calculation used to cal-
culate base excess by the blood gas analyser and the
resuscitation fluid administered were not recorded in
the database.
A further limitation is that a few early deaths may
have been missed out from the consortium set, that is,
deaths occurring at referring hospitals prior to PICU
referral. However the excellent performance of the BEP
score despite this heterogeneity may also be considered
to be a strength. Furthermore the fact that the score
performed so well in the more homogeneous replication
set, in which the first recorded sample was from presen-
tation in Emergency Department and in which early
deaths were likely to have been more reliably recorded,
suggests that the score may have high utility at this
important time point in the natural history of the
disease.
Unfortunately, it was not possible to compare the BEP
score to some previously described clinical scoring sys-
tems in this study because the data items used in those
scoring systems were not available. Therefore it is still
possible that another system based on clinical or other
data might outperform the BEP score. Furthermore,
while it would have been interesting to look at varia-
tions in performance of the BEP score over time, or
across different centres or countries, it was not possible
to do this given the nature of the data as some centres
contributed more patients in the early part of the study
period and others later. Hence it was not possible to
dissect the individual contribution of these factors.
We were also unable to compare the performance of
the BEP score to any other score in the replication data-
set from CATS, as the data needed to produce these
scores was not available retrospectively. It is also unclear
as to why the BEP score had a higher AUC in the CATS
replication dataset as compared to the validation dataset,
although this may be due to the more homogeneous
cohort which will have reliably included children who
died in the referring centre prior to PICU admission.
Conclusions
In this study, the development of a new prognostic score
for meningococcal sepsis is described. The new score,
termed the BEP score, depends on base excess and pla-
telet count at presentation. Both of these variables are
objective and easy and quick to measure. They are also
unlikely to be affected by observer error. We propose
that the BEP score should be further evaluated for mor-
tality prediction and risk stratification in meningococcal
and in other forms of bacterial sepsis, in both adults
and children.
Key messages
• A new prognostic scoring system for paediatric
meningococcal sepsis was developed and validated in
a cohort of 1,073 patients and tested in a replication
set of 134 patients.
• The score, based on base excess and platelet count
at presentation, has been named the BEP score
• Both base excess and platelet count are objective
and easy to measure
• The BEP score is both sensitive and specific in pre-
dicting death
• Further evaluation is required to determine the uti-
lity of the BEP score in other forms of sepsis
Additional material
Additional file 1: Figure S1: Histograms of the laboratory variables.
Additional file 2: Figure S2: Posterior probability distribution of the
regression coefficients estimates using Bayesian model averaging.
Additional file 3: Figure S3: Calibration curves showing agreement
between predicted and observed probability of death.
Additional file 4: Table S1: Base excess and platelet count (BEP)
score cutoff values that optimise the Youden Index and associated
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performance. Cutoff was estimated on development dataset and tested
on all other sets. PPV, positive predictive value.
Additional file 5: Figure S4: Monte-Carlo cross validation estimate
of the out of sample area under the curve (AUC) for base excess
and platelet count (BEP) and all benchmark scores using 105
random splits of the validation set into two equal sets for training
and testing BEP score. (A-C) Z-score of the DeLong test statistics for
the paired comparison between BEP and all benchmark prognosis scores.
(D-F) Histograms of the AUC for each benchmark score. (G-H)
Histograms of the BEP AUC on the set of records in common with each
benchmark score.
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